

=> dis his

(FILE 'HOME' ENTERED AT 14:02:44 ON 03 NOV 2006)

FILE 'REGISTRY' ENTERED AT 14:03:22 ON 03 NOV 2006

L1	1 S BIGUANIDE/CN
L2	1 S METFORMIN/CN
L3	1 S PHENFORMIN/CN
L4	1 S BUFORMIN/CN
L5	1 S TROGLITAZONE/CN
L6	1 S ROSIGLITAZONE/CN
L7	1 S PIOGLITAZONE/CN
L8	0 S EIGLITAZONE/CN
L9	1 S CIGLITAZONE/CN

FILE 'CAPLUS, USPATFULL' ENTERED AT 14:07:36 ON 03 NOV 2006

L10 6 S (OSMOTIC(3A)TABLET) AND (L1 OR L2 OR L3 OR L4) AND (L5 OR L6.

L10 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2006:240133 USPATFULL  
TITLE: Dual controlled release dosage form  
INVENTOR(S): Vergez, Juan A., Buenos Aires, ARGENTINA  
Ricci, Marcelo A., Buenos Aires, ARGENTINA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006204578	A1	20060914
APPLICATION INFO.:	US 2006-355315	A1	20060215 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2005-321736, filed on 29 Dec 2005, PENDING Division of Ser. No. US 2001-992488, filed on 6 Nov 2001, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INNOVAR, LLC, P O BOX 250647, PLANO, TX, 75025, US		
NUMBER OF CLAIMS:	50		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	2584		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Osmotic devices and other tablet formulations are known for their ability to provide a controlled release of a wide range of drugs. Such osmotic devices and other tablet formulations are disclosed in U.S. Pat. No. 4,014,334 to Theeuwes et al., U.S. Pat. No. 4,576,604 to Guittard et al., . . .

DETD Oxybutynin is available in controlled release osmotic device tablet dosage forms called DITROPAN.TM. XL from Alza Corporation (Palo Alto, Calif.) and called DITROPAN.TM. UD from Osmodex (Buenos Aires, Argentina) and as a non-osmotic device tablet dosage form called CYSTRIN.TM. CR from Leiras OY (Finland). Oxybutynin is released from these tablet dosage forms at a controlled. . .

DETD When the controlled release tablet is an osmotic device, osmotically effective solutes, osmotic agents or osmagents are added. These osmagents will aid in either the suspension or dissolution.

DETD . . . solution of suitable materials to provide the desired drug release profile. For example, if the tablet is to be an osmotic device, then the tablet core may be coated with a semipermeable membrane. Subsequently, the semipermeable membrane surrounding the core should be perforated with, for. . .

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, biological studies 50-99-7, Dextrose, biological studies 51-71-8, Phenelzine 52-86-8, Haloperidol 58-00-4, Apomorphine 58-38-8 58-39-9, Perphenazine 59-67-6, Nicotinic acid, biological studies 59-92-7, Levodopa, biological studies 64-77-7, Tolbutamide 69-09-0, Chlorpromazine hydrochloride 69-23-8, Fluphenazine 69-65-8, Mannitol 72-69-5, Nortriptyline 77-37-2, Procyclidine 87-69-4, Tartaric Acid, biological studies 94-20-2, Chloropropamide 102-76-1, Triacetin 117-89-5, Trifluoperazine 132-17-2, Benztropine mesylate 137-53-1, Dextrothyroxine sodium 144-11-6 155-09-9, Tranlylcypromine 298-46-4,

Carbamazepine 303-49-1, Clomipramine 321-64-2, Tacrine 322-35-0  
 339-43-5, Carbutamide 339-44-6, Glymidine 357-70-0, Galantamine  
 438-60-8, Protriptyline 451-71-8, Glyhexamide 511-45-5, Pridinol  
 514-65-8, Biperiden 535-65-9, Glybutthiazole 557-04-0, Magnesium  
 Stearate 637-07-0, Clofibrate 657-24-9, Metformin 664-95-9,  
 Tolcyclamide 739-71-9, Trimipramine 768-94-5, Amantadine 968-81-0,  
 Acetohexamide 1156-19-0, Tolazamide 1228-19-9, Glypinamide  
 1309-37-1, Ferric Oxide, biological studies 1492-02-0, Glybuzole  
 1668-19-5, Doxepin 1977-10-2, Loxapine 2062-78-4, Pimozide  
 2295-31-0, Thiazolidinedione 3149-00-6, Phenbutamide 3313-26-6,  
 Thiothixene 4618-41-1, 1-Butyl-3-metanilylurea 5588-33-0,  
 Mesoridazine 5786-21-0, Clozapine 6882-47-9, Biguanidine 7416-34-4,  
 Molindone 7631-86-9, Silicon Dioxide, biological studies 7647-14-5,  
 Sodium Chloride, biological studies 9003-39-8, Povidone 9004-34-6,  
 Cellulose, biological studies 9004-35-7 9004-38-0, Cellulose  
 Acetophthalate 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5,  
 Methylcellulose 9005-65-6, Polysorbate 80 10238-21-8, Glibenclamide  
 10262-69-8, Maprotiline 11041-12-6, Cholestyramine 13463-67-7,  
 Titanium Dioxide, biological studies 14028-44-5, Amoxapine  
 14611-51-9, Selegiline 18016-80-3, Lisuride 19794-93-5, Trazodone  
 19982-08-2, Memantine 21187-98-4, Gliclazide 23288-49-5, Probucol  
 25046-79-1, Glisoxepid 25086-89-9 25322-68-3, Polyethylene Glycol  
 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26944-48-9,  
 Glibornuride 28721-07-5, Oxcarbazepine 28860-95-9, Carbidopa  
 28981-97-7, Alprazolam 29094-61-9, Glipizide 31566-31-1 33342-05-1,  
 Gliquidone 34911-55-2, Bupropion 36282-47-0, Tramadol Hydrochloride  
 50925-79-6, Cholestipol 54739-18-3, Fluvoxamine 54910-89-3,  
 Fluoxetine 59729-33-8, Citalopram 61036-40-6, Myvacet 5-07  
 61869-08-7, Paroxetine 62571-86-2, Captopril 63675-72-9, Nisoldipine  
 66104-22-1, Pergolide 68291-97-4, Zonisamide 73573-88-3, Mevastatin  
 74811-65-7, Croscarmellose sodium 75330-75-5, Lovastatin 79617-96-2,  
 Sertraline 79902-63-9, Simvastatin 81093-37-0, Pravastatin  
 81409-90-7, Cabergoline 83366-66-9, Nefazodone 84057-84-1,  
 Lamotrigine 85650-52-8, Mirtazapine 91374-21-9, Ropinirole  
 93413-69-5, Venlafaxine 93957-54-1, Fluvastatin 97240-79-4,  
 Topiramate 97322-87-7, Troglitazone 102767-28-2,  
 Levetiracetam 104632-26-0, Pramipexole 105816-04-4, Nateglinide  
 106266-06-2, Risperidone 111025-46-8, Pioglitazone  
 111974-69-7, Quetiapine 112529-15-4, Pioglitazone hydrochloride  
 120014-06-4, Donepezil 122320-73-4, Rosiglitazone  
 123441-03-2, Rivastigmine 130929-57-6, Entacapone 132539-06-1,  
 Olanzapine 133099-07-7, Darifenacin Hydrobromide 134308-13-7,  
 Tolcapone 134523-00-5, Atorvastatin 134523-03-8, Atorvastatin calcium  
 135062-02-1, Repaglinide 136434-34-9, Duloxetine hydrochloride  
 146939-27-7, Ziprasidone 147511-69-1, Pitavastatin 149202-17-5,  
 Cellactose 156897-06-2, Licofelone 162011-90-7, Rofecoxib  
 163222-33-1, Ezetimibe 909710-69-6, Opadry Y 1-18-128A White  
 (dual controlled release osmotic device comprising two different active  
 agents)

L10 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2005:188933 USPATFULL

TITLE: Rosiglitazone and metformin formulations

INVENTOR(S): Boehm, Garth, Westfield, NJ, UNITED STATES  
 Dundon, Josephine, Fanwood, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005163842	A1	20050728
APPLICATION INFO.:	US 2004-21562	A1	20041223 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-533781P	20031231 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: CANTOR COLBURN, LLP, 55 GRIFFIN ROAD SOUTH, BLOOMFIELD,  
CT, 06002, US  
NUMBER OF CLAIMS: 25  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3119

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Rosiglitazone and metformin are drugs used to treat type 2 diabetes. Formulations comprising amorphous rosiglitazone and metformin are described. Other formulations include formulations for retention in the stomach and upper gastrointestinal tract. Controlled-release dosage forms in which the release of the rosiglitazone, the metformin, or both are controlled are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . an osmotic agent is placed in the core material. Such an osmotic agent is water soluble and will provide an osmotic pressure in the tablet. Examples of osmotic agents are magnesium sulfate, sodium chloride, lithium chloride, potassium chloride, potassium sulfate, sodium carbonate, lithium sulfate, calcium bicarbonate, sodium sulfate, . . .

IT 657-24-9, Metformin 1115-70-4, Metformin hydrochloride  
122320-73-4, Rosiglitazone 155141-29-0, Rosiglitazone maleate  
(oral rosiglitazone and metformin formulations)

=>

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	633	(osmotic same tablet) and (BIGUANIDE or METFORMIN or PHENFORMIN or BUFORMIN) and (TROGLITAZONE or ROSIGLITAZONE or PIOGLITAZONE or CIGLITAZONE)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2006/11/03 14:26
L2	223	(osmotic same tablet) and (BIGUANIDE or METFORMIN or PHENFORMIN or BUFORMIN) and (TROGLITAZONE or ROSIGLITAZONE or PIOGLITAZONE or CIGLITAZONE) and ((polyvinyl adj pyrrolidone) or (hydroxypropyl adj cellulose) or (hydroxyethyl adj cellulose) or (hydroxypropyl adj methylcellulose) or ethylcellulose or polymethacrylate or polyvinylalcohol or wax) and ((capric adj acid) or (oleic adj acid))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2006/11/03 14:32
L3	7482	(osmotic same tablet) and (BIGUANIDE or METFORMIN or PHENFORMIN or BUFORMIN) and (TROGLITAZONE or ROSIGLITAZONE or PIOGLITAZONE or CIGLITAZONE) and ((polyvinyl adj pyrrolidone) or (hydroxypropyl adj cellulose) or (hydroxyethyl adj cellulose) or (hydroxypropyl adj methylcellulose) or ethylcellulose or polymethacrylate or polyvinylalcohol or wax) and ((capric adj acid) or (oleic adj acid)) and (((sodium adj lauryl) adj sulfate) and (sodium adj taurocholate) or (polysorbate adj "80")) and (citric adj acid) or (phytic adj acid) or (ethylendiamine adj (tetraacetic adj acid))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2006/11/03 14:56

## EAST Search History

L4	7465	(osmotic same tablet) and (BIGUANIDE or METFORMIN or PHENFORMIN or BUFORMIN) and (TROGLITAZONE or ROSIGLITAZONE or PIOGLITAZONE or CIGLITAZONE) and ((polyvinyl adj pyrrolidone) or (hydroxypropyl adj cellulose) or (hydroxyethyl adj cellulose) or (hydroxypropyl adj methylcellulose) or ethylcellulose or polymethacrylate or polyvinylalcohol or wax) and ((capric adj acid) or (oleic adj acid)) and (((sodium adj lauryl) adj sulfate) and (sodium adj taurocholate) or (polysorbate adj "80")) and (citric adj acid) or (phytic adj acid) or (ethylendiamine adj (tetraacetic adj acid)) and @ad<"20020920"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2006/11/03 15:19
L5	7470	(osmotic same tablet) and (BIGUANIDE or METFORMIN or PHENFORMIN or BUFORMIN) and (TROGLITAZONE or ROSIGLITAZONE or PIOGLITAZONE or CIGLITAZONE) and ((polyvinyl adj pyrrolidone) or (hydroxypropyl adj cellulose) or (hydroxyethyl adj cellulose) or (hydroxypropyl adj methylcellulose) or ethylcellulose or polymethacrylate or polyvinylalcohol or wax) and ((capric adj acid) or (oleic adj acid)) and (((sodium adj lauryl) adj sulfate) or (sodium adj taurocholate) or (polysorbate adj "80")) and (citric adj acid) or (phytic adj acid) or (ethylendiamine adj (tetraacetic adj acid)) and @ad<"20020920"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2006/11/03 15:21

## EAST Search History

L6	5	(osmotic same tablet) and (BIGUANIDE or METFORMIN or PHENFORMIN or BUFORMIN) and (TROGLITAZONE or ROSIGLITAZONE or PIOGLITAZONE or CIGLITAZONE) and ((polyvinyl adj pyrrolidone) or (hydroxypropyl adj cellulose) or (hydroxyethyl adj cellulose) or (hydroxypropyl adj methylcellulose) or ethylcellulose or polymethacrylate or polyvinylalcohol or wax) and ((capric adj acid) or (oleic adj acid)) and (((sodium adj lauryl) adj sulfate) or (sodium adj taurocholate) or (polysorbate adj "80")) and ((citric adj acid) or (phytic adj acid) or (ethylendiamine adj (tetraacetic adj acid))) and @ad<"20020920"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2006/11/03 15:27
L7	2	us-20060204578-\$.did.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2006/11/03 15:28